BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

...$275 million takeout of preclinical myeloid-focused company Pionyr Immunotherapeutics Inc....
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...oncology deals with Jounce Therapeutics Inc. (NASDAQ:JNCE), Pionyr Immunotherapeutics Inc....
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...taken 49.9% stakes and options to buy Pionyr Immunotherapeutics Inc....
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

...Pharmaceutical Co. Ltd. Shire plc Bristol Myers Squibb Co. Celgene Corp. Johnson & Johnson Actelion Ltd. Gilead Sciences Inc. Galapagos N.V. Arcus Biosciences Inc. Pionyr Immunotherapeutics Inc. Deals M&A Partnerships...
BioCentury | Jun 24, 2020
Deals

Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles

...act as checkpoint inhibitors for macrophages, promoting phagocytosis of tumor cells. Its latest deal, with Pionyr Immunotherapeutics...
...Gilead’s NK cell and CAR T cell pipelines, respectively. Karen Tkach Tuzman, Associate Editor Gilead Sciences Inc. Arcus Biosciences Pionyr Immunotherapeutics Inc. oNKo-Innate...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

...Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay $275 million up front to acquire 49.9% of Pionyr Immunotherapeutics Inc....
...cells 1 TREM2 - Triggering receptor expressed on myeloid cells 2 Sandi Wong, Assistant Editor Gilead Sciences Inc. Pionyr Immunotherapeutics Inc. Triggering...
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

...invested from the second. Platform plays in Vida’s portfolio also include Kronos Bio Inc. and Pionyr Immunotherapeutics Inc....
BioCentury | Apr 6, 2018
Financial News

Vida launches with $295M

...Homology Medicines Inc. (NASDAQ:FIXX), which raised $165.6 million in its IPO in March; cancer company Pionyr Immunotherapeutics Inc....
...see BioCentury, Dec. 14, 2017 ). Vida Ventures, Boston, Mass. Jaime De Leon HMI-102 Cellectis S.A. Homology Medicines Inc. Pfizer Inc. Pionyr Immunotherapeutics Inc. Vida...
BioCentury | Apr 3, 2018
Financial News

Vida launches with $295M

...Homology Medicines Inc. (NASDAQ:FIXX), which raised $165.6 million in its IPO last week; cancer company Pionyr Immunotherapeutics Inc....
...candidate in 2019 (see BioCentury Extra, Dec. 13, 2017) . Jaime De Leon Cellectis S.A. Homology Medicines Inc. Pfizer Inc. Pionyr Immunotherapeutics Inc. Vida...
BioCentury | Dec 15, 2017
Financial News

Pionyr raises $62M series B

...On Dec. 13, Pionyr Immunotherapeutics Inc. (San Francisco, Calif.) raised $62 million in a series B round led...
...Vida's Arjun Goyal will join as a board observer. Pionyr Immunotherapeutics Inc., San Francisco, Calif. Allison Johnson New Enterprise Associates OrbiMed Pionyr Immunotherapeutics Inc. Sofinnova...
Items per page:
1 - 10 of 13
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

...$275 million takeout of preclinical myeloid-focused company Pionyr Immunotherapeutics Inc....
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...oncology deals with Jounce Therapeutics Inc. (NASDAQ:JNCE), Pionyr Immunotherapeutics Inc....
BioCentury | Sep 1, 2020
Deals

Gilead deal clears path for Jounce to advance immuno-oncology programs

...taken 49.9% stakes and options to buy Pionyr Immunotherapeutics Inc....
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

...Pharmaceutical Co. Ltd. Shire plc Bristol Myers Squibb Co. Celgene Corp. Johnson & Johnson Actelion Ltd. Gilead Sciences Inc. Galapagos N.V. Arcus Biosciences Inc. Pionyr Immunotherapeutics Inc. Deals M&A Partnerships...
BioCentury | Jun 24, 2020
Deals

Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles

...act as checkpoint inhibitors for macrophages, promoting phagocytosis of tumor cells. Its latest deal, with Pionyr Immunotherapeutics...
...Gilead’s NK cell and CAR T cell pipelines, respectively. Karen Tkach Tuzman, Associate Editor Gilead Sciences Inc. Arcus Biosciences Pionyr Immunotherapeutics Inc. oNKo-Innate...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

...Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay $275 million up front to acquire 49.9% of Pionyr Immunotherapeutics Inc....
...cells 1 TREM2 - Triggering receptor expressed on myeloid cells 2 Sandi Wong, Assistant Editor Gilead Sciences Inc. Pionyr Immunotherapeutics Inc. Triggering...
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

...invested from the second. Platform plays in Vida’s portfolio also include Kronos Bio Inc. and Pionyr Immunotherapeutics Inc....
BioCentury | Apr 6, 2018
Financial News

Vida launches with $295M

...Homology Medicines Inc. (NASDAQ:FIXX), which raised $165.6 million in its IPO in March; cancer company Pionyr Immunotherapeutics Inc....
...see BioCentury, Dec. 14, 2017 ). Vida Ventures, Boston, Mass. Jaime De Leon HMI-102 Cellectis S.A. Homology Medicines Inc. Pfizer Inc. Pionyr Immunotherapeutics Inc. Vida...
BioCentury | Apr 3, 2018
Financial News

Vida launches with $295M

...Homology Medicines Inc. (NASDAQ:FIXX), which raised $165.6 million in its IPO last week; cancer company Pionyr Immunotherapeutics Inc....
...candidate in 2019 (see BioCentury Extra, Dec. 13, 2017) . Jaime De Leon Cellectis S.A. Homology Medicines Inc. Pfizer Inc. Pionyr Immunotherapeutics Inc. Vida...
BioCentury | Dec 15, 2017
Financial News

Pionyr raises $62M series B

...On Dec. 13, Pionyr Immunotherapeutics Inc. (San Francisco, Calif.) raised $62 million in a series B round led...
...Vida's Arjun Goyal will join as a board observer. Pionyr Immunotherapeutics Inc., San Francisco, Calif. Allison Johnson New Enterprise Associates OrbiMed Pionyr Immunotherapeutics Inc. Sofinnova...
Items per page:
1 - 10 of 13